Join our daily newsletter At The Bell to receive exclusive market insights
- Alexium International (AJX) appoints Billy Blackburn as CEO and Managing Director, effective September 1
- Mr Blackburn has an accomplished background, having founded a high-growth technology company that specialised in high purity solvents
- In this role he was responsible for substantial revenue growth which came through securing major consumer healthcare contracts
- Mr Blackburn will be taking over from Dr Robert Brookins who has been appointed Chief Technology Officer and will remain an Executive Director
- Alexium is down 12.5 per cent on the market with shares trading at 2.1 cents at 2:14 pm AEST
Alexium International (AJX) has appointed Billy Blackburn as CEO and Managing Director, effective September 1.
Mr Blackburn has an accomplished background, having founded a high-growth technology company that specialised in high purity solvents.
This company was sold to Nova Molecular where Mr Blackburn was appointed Vice President, Business Development.
In this role he was responsible for substantial revenue growth which came through securing major consumer healthcare contracts.
Most recently, Mr Blackburn was Vice President & Executive Manager with Giant Cement Holdings.
“I am very excited to join the team at Alexium. The business has an excellent product offering that exceeds the demands of an ever-changing marketplace,” Mr Blackburn commented.
“The team has deep technical expertise and is capable of supporting the growing customer base while delivering continued product innovation. My efforts will be focused on aggressive commercialisation of the proven technologies and delivering a sustained growth strategy.”
Mr Blackburn will be taking over from Dr Robert Brookins who has been appointed Chief Technology Officer and will remain an Executive Director.
“We are delighted to announce the appointment of Mr Blackburn given his 20 years of extensive commercial experience with high-growth technology companies,” Chair Rosheen Garnon said.
“This appointment comes at an important time in the Alexium growth cycle with the management team now heavily focused on commercialisation,” he said.
“With the number of commercial opportunities currently being pursued, it is crucial that we drive revenue growth and Mr Blackburn’s experience will complement our management team’s skill sets.
“In particular, this will enable Dr. Brookins, as Chief Technology Officer, to focus on product innovation and development, as well as customer product adoption.”
Alexium was down 12.5 per cent on the market with shares trading at 2.1 cents at 2:14 pm AEST.
